Additional Details

  • Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

    University of California, Los Angeles (Site #: 71123)
    Los Angeles CA. 90095
    View Details
  • Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

    Cleveland Clinic (Site #: 71101)
    Cleveland OH. 44195
    View Details
  • Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

    University Health Network/Toronto General Hospital (Site #: 71121)
    Toronto ON. M5G 2N2
    View Details
  • Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

    Johns Hopkins (Site #: 71119)
    Baltimore MD. 21287
    View Details
  • Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

    Duke University (Site #: 71139)
    Durham NC. 27710
    View Details
  • Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

    MD Anderson Cancer Center
    Houston TX. 77030
    View Details
  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Trois-Rivières QC. G8T 7A1
    View Details
  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Ajax ON. L1S 2J5
    View Details
  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Montréal QC. H2X 0A9
    View Details
  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Edmonton AB. T6G 2C8
    View Details
  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Sherbrooke QC. J1H 5N4
    View Details
  • A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

    Research Site
    Vancouver BC. V6Z 2K5
    View Details
  • Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

    University of California San Francisco
    San Francisco CA. 94143
    View Details
  • Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

    University of Michigan
    Ann Arbor MI. 48109
    View Details
  • Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

    University of Kansas
    Kansas City KS. 66103
    View Details
  • Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

    University of Colorado Denver
    Aurora CO. 80045
    View Details
  • DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    Marshall Health
    Huntington WV. 25701
    View Details
  • DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    Baylor University Medical Center
    Dallas TX. 75246
    View Details
  • DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    Oregon Health & Science University
    Portland OR. 97239
    View Details
  • DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    Norton Pulmonary Specialists
    Louisville KY. 40202
    View Details